Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial ...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
In a sign of the emergence of Axonics Modulation Technologies Inc., which is expected to explode in revenue next year, mega medical device maker Medtronic PLC sued the small Irvine-based company for ...
Hot on the heels of the U.S. launch of its recharge-free neurostimulation implant to treat incontinence, Axonics is bringing yet another of its sacral neuromodulation (SNM) devices to our neighbors to ...
Axonics Modulation Technologies (AXNX) intends to raise $100 million from the sale of its common stock in an IPO, per an amended registration statement. The company is developing a sacral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback